Literature DB >> 20195168

Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.

Peh Sun Loo1, Stuart C Thomas, Marianne C Nicolson, Margaret N Fyfe, Keith M Kerr.   

Abstract

INTRODUCTION: The emergence of treatments for non-small cell lung carcinoma (NSCLC) with differential efficacy and toxicity between subtypes has highlighted the importance of specific pathologic NSCLC subtyping. Most NSCLCs are inoperable, and pathologic diagnosis is made only on small tissue samples that are prone to diagnostic inaccuracy. In a substantial proportion of cases, standard morphology cannot specifically subtype the tumor, necessitating a diagnosis of NSCLC-not otherwise specified (NOS). Histochemical staining for mucin and immunohistochemical (IHC) identification of NSCLC subtype-associated markers could help predict the final subtype of resected NSCLCs diagnosed as NSCLC-NOS on preoperative bronchial biopsy samples.
METHODS: Paraffin sections of 44 bronchial biopsy samples diagnosed as NSCLC-NOS were stained for mucin (Alcian blue/periodic acid Schiff) and thyroid transcription factor 1 by IHC-(markers of adenocarcinoma), and for S100A7, cytokeratin 5/6, high molecular weight cytokeratins, and p63 proteins-markers of squamous cell carcinoma. A predictive staining panel was derived from statistical analysis after comparing staining profiles with the final postsurgical NSCLC subtype. This panel was prospectively applied to 82 small biopsy samples containing NSCLC.
RESULTS: True NSCLC subtype of undifferentiated NSCLC samples was best predicted using Alcian blue/periodic acid Schiff plus p63 and thyroid transcription factor 1 IHC, allowing specific subtyping in 73% of NSCLC-NOS cases with 86% accuracy. When applied prospectively, this staining panel showed 100% concordance with specific NSCLC morphologic subtyping in small biopsies.
CONCLUSION: This approach can facilitate treatment selection by accurately predicting the subtype in undifferentiated NSCLC biopsies, reducing to 7% the proportion of cases without a definite or probable histologic subtype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195168     DOI: 10.1097/JTO.0b013e3181d40fac

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  47 in total

Review 1.  Should we continue to use the term non-small-cell lung cancer?

Authors:  A F Gazdar
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

2.  The evolving role of the pathologist in the management of lung cancer.

Authors:  Adi F Gazdar
Journal:  Lung Cancer Manag       Date:  2012

Review 3.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

4.  An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.

Authors:  Luc Girard; Jaime Rodriguez-Canales; Carmen Behrens; Debrah M Thompson; Ihab W Botros; Hao Tang; Yang Xie; Natasha Rekhtman; William D Travis; Ignacio I Wistuba; John D Minna; Adi F Gazdar
Journal:  Clin Cancer Res       Date:  2016-06-28       Impact factor: 12.531

5.  A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens.

Authors:  Diana Montezuma; Rosa Azevedo; Paula Lopes; Renata Vieira; Ana Luísa Cunha; Rui Henrique
Journal:  Virchows Arch       Date:  2013-10-15       Impact factor: 4.064

6.  ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens.

Authors:  Wei Zhao; Hui Wang; Yan Peng; Bo Tian; Lei Peng; Da-Chuan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 7.  The lung adenocarcinoma guidelines: what to be considered by surgeons.

Authors:  Rodrigo A S Sardenberg; Evandro Sobroza Mello; Riad N Younes
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 8.  Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.

Authors:  Swaroop Revannasiddaiah; Priyanka Thakur; Bhaskar Bhardwaj; Sridhar Papaiah Susheela; Irappa Madabhavi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

9.  Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.

Authors:  Erik Thunnissen; Evan Boers; Daniëlle A M Heideman; Katrien Grünberg; Dirk J Kuik; Arnold Noorduin; Matthijs van Oosterhout; Divera Pronk; Cees Seldenrijk; Hannie Sietsma; Egbert F Smit; Robertjan van Suylen; Jan von der Thusen; Bart Vrugt; Anne Wiersma; Birgit I Witte; Michael den Bakker
Journal:  Virchows Arch       Date:  2012-10-12       Impact factor: 4.064

10.  The value of AGR2 and KRT5 as an immunomarker combination in distinguishing lung squamous cell carcinoma from adenocarcinoma.

Authors:  Bo Pan; Zi-Xin Wei; Ju-Xuan Zhang; Xin Li; Qing-Wei Meng; Ying-Yue Cao; Li-Shuang Qi; Yan Yu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.